Biovail Says Tiazac Andrx Settlement “Satisfies” FTC; Patent Remains Listed
Executive Summary
Biovail's Tiazac patent litigation settlement with Andrx satisfies the Federal Trade Commission's concerns regarding late-listed Tiazac patents, Biovail says
You may also be interested in...
FTC/Biovail Tiazac Settlement Blocks Royalties From Andrx On Generic
The Federal Trade Commission consent order with Biovail regarding Tiazac voids a proposed settlement between the company and Andrx
FTC/Biovail Tiazac Settlement Blocks Royalties From Andrx On Generic
The Federal Trade Commission consent order with Biovail regarding Tiazac voids a proposed settlement between the company and Andrx
FTC To Testify On Generic Reform; Agency Report May Be “Months” Away
Patent licensing deals that relate exclusively to listing in FDA's "Orange Book" will attract antitrust scrutiny, FTC Office of Policy Planning Director Ted Cruz said